CRISPR CPF1 direct repeat variants
US12264323B2 · kind B2 · utility
0Cited by
7References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 17, 2019 |
| Grant date | Apr 1, 2025 |
| Priority date | — |
| Expiry date | Jun 27, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14143
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention generally relates to systems, methods and compositions related to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and components thereof. Provided herein are engineered Cpf1 polynucleotides that can direct the activity of a CRISPR protein to multiple targets using a single crRNA. The guide sequences can target a sequence in a eukaryotic cell, for example, an animal or a plant cell. The animal cell can be a human or a nonhuman cell. Additionally, the present invention relates to methods for developing or designing CRISPR-Cas system-based therapy or therapeutics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.